New drug cocktail aims to boost CAR T-Cell success in lymphoma
NCT ID NCT06209619
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether adding two drugs—CC-99282 and rituximab—can help people with non-Hodgkin lymphoma who didn't get a good result from CAR T-cell therapy. The study will enroll 18 adults with relapsed or refractory B-cell lymphoma. Researchers are looking for the safest dose and checking for side effects, while also seeing if the combo can stop the cancer from growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Golcadomide (CC-99282) plus rituximab
- What this could lead to
- If this works, it could offer a new treatment option for lymphoma patients who don't respond well to CAR T-cell therapy, potentially improving their chances of staying cancer-free.
- What could go wrong
- This is a very early phase 1 trial with only 18 participants, so the safety and effectiveness are not yet proven. The drug combo may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA-RECURRENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo outsmart returning lymphoma?
- New combo therapy aims to stop aggressive lymphoma relapse
- New combo aims to boost CAR-T safety in lymphoma patients
- New hope for lymphoma patients after CAR T-Cell failure
- New combo aims to boost CAR T-Cell therapy for rare lymphoma
- New antibody drug may boost transplant success in tough lymphoma